tbuckley/cabot-search huggingface dataset:
Impact of COVID-19 on breast cancer care at a Bay Area academic center
Authors: J. L. Wu, S. Bobo, S. Henry, M. Mills, A. Kurian, F. Dirbas
Journal: Cancer Research (2021)

Background: Oncology practice has been transformed in response to the COVID-19 pandemic  Oncologists arepostponing chemotherapies, delaying curative surgeries, and switching intravenous to oral therapies  Thesedecisions are based on competing risks, and treatments are proceeding if the malignancy is more lethal than thevirus  There is currently limited information quantifying the impact of COVID-inspired policies on breast cancer care Methods: This is a retrospective analysis of all patients with a new diagnosis of breast cancer between October 1,2019 and May 27, 2020, and who had a stage documented in the Stanford electronic medical record (EMR)  Caseswho had a recurrence of previously diagnosed breast cancer or who had their breast cancer care primarily outsideof Stanford and did not have their outside health records accessible were excluded  Changes in treatment plan dueto COVID-19 were defined as including “COVID” or “coronavirus” in the clinical medical decision makingdocumented in clinical notes supporting any treatment decision affecting timing or type of systemic therapy, surgery,or radiation  This includes treatment affected by new policies because of COVID-19 or concerns expressed by theprovider or patient due to COVID-19  If treatment was changed and no rationale was given, this was categorized as“unknown ” If patients experienced a change in other breast cancer treatment-related services (for example,physical therapy for lymphedema) due to COVID, this was categorized as “other” and not included in the analysis Treatment changes were noted if documented prior to June 26, 2020 Results: 291 cases were analyzed  Overall,the majority had early stage disease (Stage 0 or 1;n = 190, 65 3%) ( Table 1 )  46 (15 8%) patients had a change intherapy (systemic therapy, surgery, or radiation)  The most common treatment change was a delay of surgery (n = )  There was no significant difference in the agesof patients who had a COVID-related treatment change (all patients: mean 56 9 years old at diagnosis;patients withtreatment change: mean 57 0 years old)  Another 20 (6 9%) patients had a change in other breast cancer treatment-related services due to COVID-19 related causes Conclusions: During the COVID-19 outbreak, a significant minorityof patients with recently diagnosed breast cancer had their treatment plan changed in response to COVID-19  Inparticular, patients with early stage breast cancers who were candidates for neoadjuvant endocrine therapy hadsurgeries delayed  Further follow-up will be needed to fully understand the impact COVID-19 has had on cancercare, as more recently diagnosed patients have not yet completed treatment  However, this early analysis can beginto quantify the impact of COVID-19 on cancer care  (Table Presented)
P50.12 A Novel Nomogram and Risk Classification System Predicting The Survival of Patients with Extensive-stage Small Cell Lung Cancer
Authors: T. Mei, X. Yang, W. Xiu, Y. Yu, J. Zhu, Y. Zhang, M. Huang, F. Peng, M. Yu, Y. Li, L. Zhou, J. Xue, X. Zhou, Y. Liu, B. Zou, Y. Xu, Y. Wang, Y. Lu, Y. Gong
Journal: Journal of Thoracic Oncology (2021)
Accurate <i>in vivo</i> tumor detection using plasmonic-enhanced shifted-excitation Raman difference spectroscopy (SERDS)
Authors: Strobbia, Pietro, Cupil-Garcia, Vanessa, Crawford, Bridget M., Fales, Andrew M., Pfefer, T. Joshua, Liu, Yang, Maiwald, Martin, Sumpf, Bernd, Vo-Dinh, Tuan
Journal: Theranostics (2021)

For the majority of cancer patients, surgery is the primary method of treatment. In these cases, accurately removing the entire tumor without harming surrounding tissue is critical; however, due to the lack of intraoperative imaging techniques, surgeons rely on visual and physical inspection to identify tumors. Surface-enhanced Raman scattering (SERS) is emerging as a non-invasive optical alternative for intraoperative tumor identification, with high accuracy and stability. However, Raman detection requires dark rooms to work, which is not consistent with surgical settings. Methods: Herein, we used SERS nanoprobes combined with shifted-excitation Raman difference spectroscopy (SERDS) detection, to accurately detect tumors in xenograft murine model. Results: We demonstrate for the first time the use of SERDS for in vivo tumor detection in a murine model under ambient light conditions. We compare traditional Raman detection with SERDS, showing that our method can improve sensitivity and accuracy for this task. Conclusion: Our results show that this method can be used to improve the accuracy and robustness of in vivo Raman/SERS biomedical application, aiding the process of clinical translation of these technologies.
Role of Hematological Parameters in Predicting Severity of Acute Venous Thromboembolism
Authors: Supreet Kaur, Anusha Manje Gowda, Abhishek Kumar, Ammad Ishfaq, Rashika Bansal, Astha Agrawal, Balraj Singh, Rahul Vasudev, Michael Maroules
Journal: Blood (2017)
Mitigating the environmental impact of plastic PPE: more than just disposal
Authors: Li Fang, Annie Pinder, Glen Cooper, Brendan McGrath, Cliff Shelton
Journal: BMJ (2021)

Zhang and colleagues discuss the environmental consequences of disposing of single use personal protective equipment (PPE).1 But there are crucial steps before disposal that incorporate the “5 Rs”: reduce, reuse, recycle, research, and rethink.2

With cumulative use, even simple PPE has major consequences. A standard box of nitrile gloves, for example, has the same CO2 equivalent as driving 20 miles in a petrol car.3 Simple and effective ways of minimising unnecessary PPE …
Migraine: integrated approaches to clinical management and emerging treatments
Authors: Messoud Ashina, Dawn C Buse, Håkan Ashina, Patricia Pozo-Rosich, Mario F P Peres, Mi Ji Lee, Gisela M Terwindt, Rashmi Halker Singh, Cristina Tassorelli, Thien Phu Do, Dimos D Mitsikostas, David W Dodick
Journal: The Lancet (2021)
CD47‐Mediated Hedgehog/SMO/GLI1 Signaling Promotes Mesenchymal Stem Cell Immunomodulation in Mouse Liver Inflammation
Authors: Mingwei Sheng, Yuanbang Lin, Dongwei Xu, Yizhu Tian, Yongqiang Zhan, Changyong Li, Douglas G. Farmer, Jerzy W. Kupiec‐Weglinski, Bibo Ke
Journal: Hepatology (2021)

The cluster of differentiation 47 (CD47)-signal regulatory protein alpha (SIRPα) signaling pathway plays important roles in immune homeostasis and tissue inflammatory response. Activation of the Hedgehog/smoothened (SMO)/GLI family zinc finger 1 (Gli1) pathway regulates cell growth, differentiation, and immune function. However, it remains unknown whether and how the CD47-SIRPα interaction may regulate Hedgehog/SMO/Gli1 signaling in mesenchymal stem cell (MSC)-mediated immune regulation during sterile inflammatory liver injury.In a mouse model of ischemia/reperfusion (IR)-induced sterile inflammatory liver injury, we found that adoptive transfer of MSCs increased CD47 expression and ameliorated liver IR injury. However, deletion of CD47 in MSCs exacerbated IR-induced liver damage, with increased serum ALT levels, macrophage/neutrophil infiltration, and pro-inflammatory mediators. MSC treatment augmented SIRPα, Hedgehog/SMO/Gli1, and Notch1 intracellular domain (NICD), whereas CD47-deficient MSC treatment reduced these gene expressions in IR-stressed livers. Moreover, disruption of myeloid SMO or Notch1 increased IR-triggered liver inflammation with diminished Gli1 and NICD, but enhanced NIMA related kinase 7 (NEK7) and NLR family pyrin domain containing 3 (NLRP3) activation in MSC-transferred mice. Using a MSC/macrophage co-culture system, we found that MSC CD47 and macrophage SIRPα expression were increased after LPS stimulation. The CD47-SIRPα interaction increased macrophage Gli1 and NICD nuclear translocation, whereby NICD interacted with Gli1 and regulated its target gene Dvl2 (dishevelled segment polarity protein 2), which in turn inhibited NEK7/NLRP3 activity.The CD47-SIRPα signaling activates the Hedgehog/SMO/Gli1 pathway, which controls NEK7/NLRP3 activity through a direct interaction between Gli1 and NICD. NICD is a coactivator of Gli1, and the target gene Dvl2 regulated by the NICD-Gli1 complex is crucial for the modulation of NLRP3-driven inflammatory response in MSC-mediated immune regulation. Our findings provide potential therapeutic targets in MSC-mediated immunotherapy of sterile inflammatory liver injury.
BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers
Authors: Shmuel Benenson, Yonatan Oster, Matan J Cohen, Ran Nir-Paz
Journal: New England Journal of Medicine (2021)

BNT162b2 Efficacy among Israeli Health Care Workers A systematic program to vaccinate health care workers at Hadassah Medical Center demonstrated a high level of effective prevention of Covid-19 be...
A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY)
Authors: Pablo E. Pergola, David P. Rosenbaum, Yang Yang, Glenn M. Chertow
Journal: Journal of the American Society of Nephrology (2021)

Hyperphosphatemia is associated with cardiovascular morbidity and mortality in patients receiving maintenance dialysis. It is unknown whether combining two therapies with different mechanisms of action-tenapanor, an inhibitor of paracellular phosphate absorption, and phosphate binders-is safe and effective for the management of hyperphosphatemia in patients receiving maintenance dialysis.This double-blind phase 3 trial enrolled 236 patients undergoing maintenance dialysis with hyperphosphatemia (defined in this trial as serum phosphorus 5.5-10 mg/dl inclusive) despite receiving phosphate binder therapy (sevelamer, nonsevelamer, sevelamer plus nonsevelamer, or multiple nonsevelamer binders). These participants were randomly assigned to receive oral tenapanor 30 mg twice daily or placebo for 4 weeks. The primary efficacy end point was the change in serum phosphorus concentration from baseline to week 4.Of the 236 randomized patients, 235 (99.6%) were included in the full analysis set; this included 116 in the tenapanor plus binder group and 119 in the placebo plus binder group. A total of 228 patients (96.6%) completed the 4-week treatment period. In the full analysis set (mean age 54.5 years, 40.9% women), patients treated with tenapanor plus binder achieved a larger mean change in serum phosphorus concentration from baseline to week 4 compared with placebo plus binder (-0.84 versus -0.19 mg/dl, P<0.001). Diarrhea was the most commonly reported adverse event, resulting in study drug discontinuation in four of 119 (3.4%) and two of 116 (1.7%) patients receiving tenapanor plus binder or placebo plus binder, respectively.A dual-mechanism treatment using both tenapanor and phosphate binders improved control of hyperphosphatemia in patients undergoing maintenance dialysis compared with phosphate binders alone.AMPLIFY, NCT03824587.
Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
Authors: Dristhi Ragoonanan, Sajad J. Khazal, Hisham Abdel-Azim, David McCall, Branko Cuglievan, Francesco Paolo Tambaro, Ali Haider Ahmad, Courtney M. Rowan, Cristina Gutierrez, Keri Schadler, Shulin Li, Matteo Di Nardo, Linda Chi, Alison M. Gulbis, Basirat Shoberu, Maria E. Mireles, Jennifer McArthur, Neena Kapoor, Jeffrey Miller, Julie C. Fitzgerald, Priti Tewari, Demetrios Petropoulos, Jonathan B. Gill, Christine N. Duncan, Leslie E. Lehmann, Sangeeta Hingorani, Joseph R. Angelo, Rita D. Swinford, Marie E. Steiner, Fiorela N. Hernandez Tejada, Paul L. Martin, Jeffery Auletta, Sung Won Choi, Rajinder Bajwa, Natalie Dailey Garnes, Partow Kebriaei, Katayoun Rezvani, William G. Wierda, Sattva S. Neelapu, Elizabeth J. Shpall, Selim Corbacioglu, Kris M. Mahadeo
Journal: Nature Reviews Clinical Oncology (2021)
Air pollution and chronic bronchitis: the evidence firms up
Authors: Frank Kelly
Journal: Thorax (2021)

Chronic bronchitis is defined epidemiologically as cough and sputum production for ≥3 months in each of at least two consecutive years.1 It affects about a third of patients with chronic obstructive pulmonary disease but also occurs in individuals with normal lung function, with prevalence estimates varying widely.2–7 While it is not, by itself, associated with a substantially higher risk of death,8 it is associated with exacerbations of disease, incapacity and poor quality of life. The identification of chronic bronchitis was standardised in the first instance by the British Medical Research Council questionnaire,9 and subsequently, the questions were introduced into other respiratory symptom questionnaires.

Ambient air pollution is increasingly being linked to a range of human conditions, and in the case of chronic bronchitis, which affects over two million individuals in the UK,10 there is some evidence of an association between the incidence or prevalence of chronic bronchitis and long-term exposure to air pollution.11–13 Early reports, however, relate to a time when the bulk of outdoor air pollution came from coal burning …
A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma
Authors: Xiao-Peng Tian, Shu-Yun Ma, Ken H. Young, Choon Kiat Ong, Yan-Hui Liu, Zhi-Hua Li, Qiong-Li Zhai, Hui-Qiang Huang, Tong-Yu Lin, Zhi-Ming Li, Zhong-Jun Xia, Li-Ye Zhong, Hui-Lan Rao, Mei Li, Jun Cai, Yu-Chen Zhang, Fen Zhang, Ning Su, Peng-Fei Li, Feng Zhu, Zijun Y. Xu-Monette, Esther Kam Yin Wong, Jeslin Chian Hung Ha, Lay Poh Khoo, Le Ai, Run-Fen Cheng, Jing Quan Lim, Sanjay de Mel, Siok-Bian Ng, Soon Thye Lim, Qing-Qing Cai
Journal: Blood (2021)
Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome
Authors: Yin-Huai Chen, Diane B. Zastrow, Riley D. Metcalfe, Lisa Gartner, Freia Krause, Craig J. Morton, Shruti Marwaha, Laure Fresard, Yong Huang, Chunli Zhao, Colleen McCormack, David Bick, Elizabeth A. Worthey, Christine M. Eng, Jessica Gold, None Undiagnosed Diseases Network, Stephen B. Montgomery, Paul G. Fisher, Euan A. Ashley, Matthew T. Wheeler, Michael W. Parker, Veerabahu Shanmugasundaram, Tracy L. Putoczki, Dirk Schmidt-Arras, Arian Laurence, Jonathan A. Bernstein, Michael D.W. Griffin, Holm H. Uhlig
Journal: Journal of Allergy and Clinical Immunology (2021)
Endoscopic incision and balloon dilation using the rendezvous technique for complete anastomotic obstruction after rectal low-anterior resection
Authors: Takahiro Inoue, Satoki Shichijo, Masayoshi Yasui, Yoji Takeuchi, Tomoki Michida, Ryu Ishihara
Journal: Endoscopy (2021)

Anastomotic stenosis, a major complication after low-anterior resection, can usually be treated by endoscopic balloon dilation [1] [2]. However, endoscopic management is challenging in the presence of a complete obstruction because an endoscope and other devices cannot be passed through the obstruction. Combined endoscopic incision and balloon dilation has reportedly been useful for treating complete rectal anastomotic obstruction [3]. If the patient has a stoma with double orifices, a simultaneous antegrade–retrograde approach to the obstructed anastomosis using two endoscopes may be feasible, a method known as the "rendezvous technique"[4].
FP07.08 A Pan-Canadian Validation Study for the Detection of EGFR-T790M Mutations Using Circulating Tumour DNA (ctDNA) from Blood
Authors: S. Selvarajah, S. Plante, M. Speevak, A. Vaags, E. Mccready, D. Grafodatskaya, N. Blais, D. Tran-Thanh, W. Greer, B. Lo, D. Demetrick, B. Sadikovic, R. Walton, T. Stockley, H. Feilotter, P. Joubert
Journal: Journal of Thoracic Oncology (2021)
A Possible Association Between a Nucleotide‐Binding Domain LRR‐Containing Protein Family PYD‐Containing Protein 1 Mutation and an Autoinflammatory Disease Involving Liver Cirrhosis
Authors: Hiroki Yasudo, Taiki Ando, Akie Maehara, Tomoaki Ando, Kumi Izawa, Atsushi Tanabe, Ayako Kaitani, Shigeru Nomura, Masafumi Seki, Kenichi Yoshida, Hirotsugu Oda, Yoko Okamoto, Hexing Wang, Anna Kamei, Mayuki Kojima, Meiko Kimura, Koichiro Uchida, Nobuhiro Nakano, Junichi Kaneko, Nobuyuki Ebihara, Kiyoshi Hasegawa, Toshiaki Shimizu, Junko Takita, Hideoki Ogawa, Ko Okumura, Seishi Ogawa, Naoto Tamura, Jiro Kitaura
Journal: Hepatology (2021)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma
Authors: Juan Garcia Valero, Alba Matas-Céspedes, Fabián Arenas, Vanina Rodriguez, Joaquim Carreras, Neus Serrat, Martina Guerrero-Hernández, Anella Yahiaoui, Olga Balagué, Silvia Martin, Cristina Capdevila, Lluis Hernández, Laura Magnano, Alfredo Rivas-Delgado, Stacey Tannheimer, Maria C. Cid, Elías Campo, Armando López-Guillermo, Dolors Colomer, Patricia Pérez-Galán
Journal: Leukemia (2021)

Microenvironment contributes to follicular lymphoma (FL) pathogenesis and impacts survival with macrophages playing a controversial role. In the present study, using FL primary samples and HK follicular dendritic cells (FDC) to mimic the germinal center, together with mouse models, we have analyzed the three-way crosstalk of FL-FDC-macrophages and derived therapeutic opportunities. Ex vivo primary FL-FDC co-cultures (n = 19) and in vivo mouse co-xenografts demonstrated that FL-FDC crosstalk favors tumor growth and, via the secretion of CCL2 and CSF-1, promotes monocyte recruitment, differentiation, and polarization towards an M2-like protumoral phenotype. Moreover, FL-M2 co-cultures displayed enhanced angiogenesis, dissemination, and immunosuppression. Analysis of the CSF-1/CSF-1R pathway uncovered that CSF-1 was significantly higher in serum from grade 3A FL patients, and that high CSF-1R expression in FL biopsies correlated with grade 3A, reduced overall survival and risk of transformation. Furthermore, CSF-1R inhibition with pexidartinib (PLX3397) preferentially affected M2-macrophage viability and polarization program disrupting FL-M2 positive crosstalk. In vivo CSF1-R inhibition caused M2 reduction and repolarization towards M1 macrophages and antitumor effect cooperating with anti-CD20 rituximab. In summary, these results support the role of macrophages in FL pathogenesis and indicate that CSF-1R may be a relevant prognostic factor and a novel therapeutic target cooperating with anti-CD20 immunotherapy.
P48.21 Population Pharmacokinetics and Exposure-Response with Durvalumab Plus Platinum-Etoposide in ES-SCLC: Results from CASPIAN
Authors: Y. Zheng, D. Jin, Y. Guan, M. Özgüroğlu, D. Trukhin, A. Poltoratskiy, Y. Chen, L. Havel, M. Hochmair, L. Paz-Ares, H. Jiang, J. Armstrong, C. Chen, Y.H. Liu, L. Roskos
Journal: Journal of Thoracic Oncology (2021)
P35.09 Oncogenetic Differences in Never-Smokers versus Smokers with NSCLC Adenocarcinoma Treated at the Mt Sinai Tisch Cancer Institute
Authors: M. Klein, P. Mack, S. Guin, Y. Gong, T. O'Connell, K. Ayers, Z. Li, Y. Li, T. Mullaney, W. Jappe, A. Redfern, T. Prentice, E. Schadt, M. Fink, X. Zhou, S. Newman, R. Chen, F. Hirsch
Journal: Journal of Thoracic Oncology (2021)
Error in Author Surname
Authors: Woong Jee, Chang Huh, Gwang Choi, Seong Gwang, Quoc-Dien Trinh
Journal: JAMA Dermatology (2021)

Marta García-Legaz Martínez, MD; Álvaro Martínez-Doménech, MD; Jorge Magdaleno-Tapial, MD; Cristian Valenzuela-Oñate, MD; Elena Iborra-Palau, RN; Víctor Alegre de Miquel, MD, PhD; Amparo Pérez-Ferriols, MD, PhD
Sixty seconds on . . . Dominic Cummings
Authors: Gareth Iacobucci
Journal: BMJ (2021)

<h3>Background</h3> National guidelines place an emphasis on patients, carers and health professionals being able to access specialist palliative care advice at all times (National Council for Palliative Care, 2015; Department of Health, 2008). The advice line enables this timely support and guidance. However, whilst running alongside the Inpatient Unit, the specific skills and knowledge required to handle calls can be overlooked (Carr, Lhussier &amp; Wilcockson, 2008). <h3>Aims</h3> To support all Registered Nurses working on the Inpatient Unit to feel more confident and competent in taking advice line calls (Purc- Stephenson &amp; Thrasher, 2010) delivering up to date, safe and consistent advice, whilst enabling a culture of feedback and support. <h3>Methods</h3> The development of advice line training following consultation with unit staff, feedback from other hospices and literature review, with sessions balancing specific telephone communication skills alongside clinical knowledge and practical elements (Yardley, Codling, Roberts, O’Donnell et al., 2009); The implementation of a new framework to help guide more complex calls – encouraging staff to think of completing a jigsaw puzzle without being able to see the picture on the box, and by putting together ‘pieces’ of information to guide the advice given by remembering to ‘delve’ and ‘tell me more…’; The commencement of regular feedback sessions enabling protected time for staff to ‘offload’, discuss difficult calls and for feedback and ongoing teaching from an Inpatient Unit Consultant or other palliative care professional; The development of an information pack to accompany training and an advice line resource folder for staff to reference during calls. <h3>Conclusion</h3> Acknowledging that for some staff the advice line can be stressful, the implementation of training and support has had a very positive impact, with staff reporting a more confident approach when taking calls. The new resources have been welcomed and already proven useful, particularly when dealing with medication related calls. This work is already enabling the delivery of more consistent, confident and quality advice and in time this will undoubtedly increase caller satisfaction (Moscato, Valanis, Gullion, Tanner <i>et al</i>., 2007).